Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR17031 vs insulin glargine in Chinese type 2 diabetes patients
NCT06881264Phase 3Completed
- Sponsor
- Hengrui
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui. Primary endpoint: Change in HbA1c from baseline at 26 weeks. Started Apr 2024; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06881264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881264.